8 results on '"Saudeau D"'
Search Results
2. [Creation of a regional stroke network in Tours hospital (France): consequences for stroke care and thrombolysis].
- Author
-
Debiais S, Bonnaud I, Giraudeau B, Perrotin D, Gigot JL, Saudeau D, De Toffol B, and Autret A
- Subjects
- Aged, Brain Ischemia complications, Cerebral Hemorrhage complications, Diagnosis, Differential, Emergency Medical Services, Female, Fibrinolytic Agents adverse effects, France, Humans, Intracranial Thrombosis complications, Intracranial Thrombosis drug therapy, Ischemic Attack, Transient diagnosis, Male, Middle Aged, Prospective Studies, Stroke diagnosis, Stroke etiology, Transportation of Patients, Treatment Outcome, Community Networks organization & administration, Fibrinolytic Agents therapeutic use, Stroke therapy
- Abstract
Introduction: Our university hospital serves a population of 300 000 inhabitants. Stroke is the leading cause of admission in our department of neurology. In June 2003, when the Emergency Department (ED) was closed in our institution, was created an acute stroke network (ASN), comprising 2 beds of direct admission and thrombolysis in the intensive care unit, and 4 beds dedicated to stroke care in the department of neurology, in which standardized stroke care protocols were implemented., Objective: The aim of this study was to evaluate changes in stroke care related to the creation of the ASN in terms of delays of arrival, imaging, use of intravenous (IV) thrombolysis, and outcome of patients. We conducted a prospective study during 18 months to evaluate characteristics of patients admitted with suspected stroke or transient ischemic attack (TIA) in the newly created ASN and to assess conditions of treatment with IV thrombolysis in terms of safety and efficacy. We also compared the outcome data before and after the creation of the ASN., Methods: For each patient admitted in our hospital for suspected stroke or TIA, were prospectively collected clinical and outcome data (age, mode of transport, delay of arrival after the onset of symptoms (OS), treatment with IV thrombolysis, outcome and discharge). This study was conducted in the ED during six months in 2002, and in the ASN during 18 months, for all patients admitted for stroke., Results: Three hundred and sixty four patients were admitted in the ASN. Emergency medical services (EMS) were used in half of cases for transport, and median delay of admission after the OS was 2h and 52 min. Median delay of imaging was 1 h and 45 min. Seventeen patients (8.5 p. 100 of ischemic stroke patients) were treated with IV thrombolysis, with an initial good outcome in 9 patients, 7 with a dramatic recovery). The main reason for therapeutic abstention for untreated patients admitted in the first 3 hours was a mild deficit with a NIHSS<6. Compared with the previous management in the ED, patients in the ASN were younger, had more severe neurological symptoms, the EMS transport was the main mode of transport (versus used in 17 p. 100 of cases in 2002), and the delay of admission was significantly lower: 2 h 52 versus 5 h 10 (p<0.02). After adjustment on the main predictive factors, only patients with hemorrhagic strokes had a better outcome after the creation of the ASN., Conclusions: Creation of an ASN was associated with a significant decrease of admission and imaging delays, due to a strong collaboration with EMS, and with a better outcome for hemorrhagic stroke patients. Treatment with intravenous thrombolysis in the first 3 hours could be used widely and was efficient and safe. However, the creation of dedicated stroke units for all stroke patients remains necessary to improve quality of care and outcome.
- Published
- 2007
- Full Text
- View/download PDF
3. Isolated Horner's syndrome may herald stroke.
- Author
-
de Bray JM, Baumgartner R, Guillon B, Pautot V, Dziewas R, Ringelstein EB, Sturzenegger M, Garnier P, Ducrocq X, Saudeau D, Neau JP, Larrue V, Vuillier F, Boulliat J, Verret JM, Verny C, and Dubas F
- Subjects
- Adult, Cerebral Angiography, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Horner Syndrome diagnosis, Horner Syndrome epidemiology, Stroke diagnosis, Stroke epidemiology
- Published
- 2005
- Full Text
- View/download PDF
4. Comparative study of atrial vulnerability in patients with unexplained ischemic stroke or lone atrial paroxysmal fibrillation.
- Author
-
Rouesnel P, Babuty D, Fauchier L, Saudeau D, Hurreesing R, Cosnay P, and Garnier LF
- Subjects
- Atrial Fibrillation physiopathology, Brain Ischemia physiopathology, Electrophysiology, Female, Humans, Male, Middle Aged, Prospective Studies, Stroke physiopathology, Atrial Fibrillation complications, Brain Ischemia etiology, Stroke etiology
- Abstract
Strokes have a high prevalence, with a high rate of recurrence, and about 30-40% remain of unknown cause. Some patients might have asymptomatic paroxysmal atrial fibrillation (AF) which remains the main cause of embolic events. A latent atrial arrhythmogenic substrate may induce recurrent arrhythmias, including functional abnormalities such as nonuniform refractoriness and/or anatomic abnormalities such as atrial septum aneurysm (ASA) and patent foramen ovale (PFO). In 175 patients divided into three groups (Group I: 103 patients with unexplained ischemic stroke, Group II: 48 patients with paroxysmal AF and Group III or control group: 24 patients explored for another cause), such an atrial arrhythmogenic substrate was assessed by electrophysiological study. Groups I and II had a similar high rate of inducible atrial arrhythmias compared to control group III where no arrhythmia was induced. An induced atrial arrhythmia was observed in more than 50% of patients of Group I and in more than 70% of patients of Group II without any significant difference according to age. However, in 26 young patients of Group I who had a transesophageal echocardiography, both a high rate (46%) of ASA and/or PFO and a frequent latent atrial vulnerability (LAV) were observed, compared to older patients where an atrial septum abnormality was observed in only 21% of cases. Thus, among patients with stroke of unknown cause, a high percentage of them might have asymptomatic atrial paroxysmal arrhythmia. The predictive value of the electrophysiological study for spontaneous arrhythmias and recurrence of stroke remains to be demonstrated.
- Published
- 2003
- Full Text
- View/download PDF
5. Ischaemic strokes and homozygosity for the alpha2 807T allele of the platelet collagen receptor in young monozygotic twins.
- Author
-
Maakaroun A, Regina S, Delahousse B, Saudeau D, and Gruel Y
- Subjects
- Adult, Alleles, Blood Platelets chemistry, Family Health, Genotype, Homozygote, Humans, Integrin alpha2beta1 physiology, Male, Twins, Monozygotic, Diseases in Twins genetics, Integrin alpha2beta1 genetics, Polymorphism, Single Nucleotide, Stroke genetics
- Abstract
A nucleotide 807T variant of the glycoprotein Ia gene that correlates with increased platelet surface levels of the platelet collagen receptor alpha2beta1 was recently found to be associated with an increased risk of ischaemic stroke in younger patients. We report the history of twins who developed ischaemic strokes and were shown to be homozygous for the alpha2 807T allele. The twins developed ischaemic strokes at the ages of 23 and 33 years, one of them with recurrent events. They had no conventional risk factors. Cardiac and vascular investigations were normal and no aetiology could be found. There was a family history of cerebrovascular disease. Genotyping of glycoprotein alpha2 C807 T was performed and both twins were found to be homozygous for the 807T allele. This allele probably contributed to the occurrence of strokes in these young men. Further prospective studies are needed to evaluate whether screening for this polymorphism should be considered in young patients with unexplained stroke, particularly when a positive family history was found., (Copyright 2003 Lippincott Williams & Wilkins)
- Published
- 2003
- Full Text
- View/download PDF
6. Sleep and brain lesions: a critical review of the literature and additional new cases.
- Author
-
Autret A, Lucas B, Mondon K, Hommet C, Corcia P, Saudeau D, and de Toffol B
- Subjects
- Animals, Humans, Stroke complications, Brain Diseases physiopathology, Sleep physiology, Sleep Wake Disorders etiology, Stroke physiopathology
- Abstract
We present a comprehensive review of sleep studies performed in patients with brain lesions complemented by 16 additional personal selected cases and by discussion of the corresponding animal data. The reader is cautioned about the risk of establishing an erroneous correlation between abnormal sleep and a given disorder due to the important inter and intra variability of sleep parameters among individuals. Salient points are stressed: the high frequency of post-stroke sleep breathing disorders is becoming increasingly recognised and may, in the near future, change the way this condition is managed. Meso-diencephalic bilateral infarcts induce a variable degree of damage to both waking and non-REM sleep networks producing and abnormal waking and sometimes a stage 1 hypersomnia reduced by modafinil or bromocriptine, which can be considered as a syndrome of cathecholaminergic deficiency. Central pontine lesions induce REM and non-REM sleep insomnia with bilateral lateral gaze paralysis. Bulbar stroke leads to frequent sleep breathing disorders. Polysomnography can help define the extent of involvement of various degenerative diseases. Fragmented sleep in Parkinson's disease may be preceded by REM sleep behavioural disorders. Multiple system atrophies are characterised by important sleep disorganization. Sleep waking disorganization and a specific ocular REM pattern are often seen in supra-nuclear ophtalmoplegia. In Alzheimer patients, sleep perturbations parallel the mental deterioration and are possibly related to cholinergic deficiency. Fronto-temporal dementia may be associated with an important decrease in REM sleep. Few narcoleptic syndromes are reported to be associated with a tumour of the third ventricle or a multiple sclerosis or to follow a brain trauma; all these cases raise the question whether this is a simple coincidence, a revelation of a latent narcolepsy or, as in non-DR16/DQ5 patients, a genuine symptomatic narcolepsy. Trypanosomiasis and the abnormal prion protein precociously after sleep patterns. Polysomnography is a precious tool for evaluating brain function provided it is realised under optimal conditions in stable patients and interpreted with caution. Several unpublished cases are presented: one case of pseudohypersomnia due to a bilateral thalamic infarct and corrected by modafinil, four probable late-onset autosomal recessive cerebellar ataxias without sleep pattern anomalies, six cases of fronto-temporal dementia with strong reduction in total sleep time and REMS percentage on the first polysomnographic night, one case of periodic hypersomnia associated with a Rathke's cleft cyst and four cases of suspected symptomatic narcolepsy with a DR16-DQ5 haplotype, three of which were post-traumatic without MRI anomalies, and one associated with multiple sclerosis exhibiting pontine hyper signals on MRI.
- Published
- 2001
- Full Text
- View/download PDF
7. [Recommendations for the creation of neuro-vascular units].
- Author
-
Woimant F, Hommel M, Adnet Bonte C, Baldauf E, Chedru F, Cohen A, de Broucker T, Devailly JP, Duclos H, Gaston A, Grobuis S, Kassiotis P, Levasseur M, Merland JJ, Mounier Vehier F, Nibbio A, Orgogozo JM, Outin H, Pinel F, Pruvo JP, Rancurel G, Saudeau D, Scart-Gres C, Sévène M, Touboul PJ, Vassel P, Zuber M, Arquizan C, Baron JC, Becker F, Bes A, Boulliat J, Bousser MG, Bracard S, Branchereau A, Castel JP, Caussanel JP, Civit J, Collard M, Davoine P, Deroudille L, Dumas R, Frerebeau P, Giroud M, Goldstein P, Lagarrigue J, Lejeune JP, Lestavel P, Leys D, Mahagne MH, Manelfe C, Mas JL, Masson M, Michel D, Moulin T, Perret J, Petit H, Proust B, Rouanet F, Rougemont D, Roux FX, Samson Y, and Trouillas P
- Subjects
- Brain Ischemia diagnosis, Brain Ischemia therapy, France, Humans, Quality Assurance, Health Care, Stroke diagnosis, Stroke therapy
- Published
- 2001
8. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
- Author
-
Hacke, Werner, Kaste, Markku, Bluhmki, Erich, Brozman, Miroslav, Dávalos, Antoni, Guidetti, Donata, Larrue, Vincent, Lees, Kennedy R., Medeghri, Zakaria, Machnig, Thomas, Schneider, Dietmar, Von Kummer, Rüdiger, Wahlgren, Nils, Toni, Danilo, Hacke, W, Dávalos, A, Kaste, M, von Kummer, R, Larrue, V, Toni, D, Wahlgren, N, Lees, Kr, Heiss, Wd, Lesaffre, E, Orgogozo, Jm, Bastianello, S, Wardlaw, Jm, Peyrieux, Jc, Sauce, C, Medeghri, Z, Mazenc, R, Machnig, T, Bluhmki, E, Aichner, F, Alf, C, Baumhackl, U, Brainin, M, Eggers, C, Gruber, F, Ladurner, G, Niederkorn, K, Noistering, G, Willeit, J, Vanhooren, G, Blecic, S, Bruneel, B, Caekebeke, J, Laloux, P, Simons, Pj, Thijs, V, Bar, M, Dvorakova, H, Vaclavik, D, Boysen, G, Andersen, G, Iversen, Hk, Traberg-Kristensen, B, Marttila, R, Sivenius, J, Trouillas, P, Amarenco, P, Bouillat, J, Ducrocq, X, Giroud, M, Jaillard, A, Larrieu, Jm, Leys, D, Magne, C, Mahagne, Mh, Milhaud, D, Sablot, D, Saudeau, D, Busse, O, Berrouschot, J, Faiss, Jh, Glahn, J, Görtler, M, Grau, A, Grond, M, Haberl, R, Hamann, G, Hennerici, M, Koch, H, Krauseneck, P, Marx, J, Meves, S, Meyding-Lamadé, U, Ringleb, P, Schneider, D, Schwarz, A, Sobesky, J, Urban, P, Karageorgiou, K, Komnos, A, Csányi, A, Csiba, L, Valikovics, A, Agnelli, G, Billo, G, Bovi, P, Comi, G, Gigli, G, Guidetti, D, Inzitari, D, Marcello, N, Marini, C, Orlandi, G, Pratesi, M, Rasura, M, Semplicini, A, Serrati, C, Tassinari, T, Brouwers, Pj, Stam, J, Naess, H, Indredavik, B, Kloster, R, Czlonkowska, A, Kuczyńska-Zardzewialy, A, Nyka, W, Opala, G, Romanowicz, S, Cunha, L, Correia, C, Cruz, V, Pinho e Melo, T, Brozman, M, Dvorak, M, Garay, R, Krastev, G, Kurca, E, Alvarez-Sabin, J, Chamorro, A, del Mar Freijo Guerrero, M, Herrero, Ja, Gil-Peralta, A, Leira, R, Martí-Vilalta, Jl, Masjuan Vallejo, J, Millán, M, Molina, C, Mostacero, E, Segura, T, Serena, J, Vivancos Mora, J, Danielsson, E, Cederin, B, Von, Zweigberg, Wahlgren, Ng, Welin, L, Lyrer, P, Bogousslavsky, J, Hungerbühler, Hj, Weder, B, Ford, Ga, Jenkinson, D, Macleod, Mj, Macwalter, Rs, Markus, Hs, Muir, Kw, Sharma, Ak, Walters, Mr, Warburton, Ea, ACS - Amsterdam Cardiovascular Sciences, ANS - Amsterdam Neuroscience, and Neurology
- Subjects
Adult ,Male ,Time Factors ,medicine.medical_treatment ,Placebo ,Drug Administration Schedule ,Brain Ischemia ,Brain ischemia ,Double-Blind Method ,Fibrinolytic Agents ,Modified Rankin Scale ,medicine ,Odds Ratio ,Desmoteplase ,Humans ,Infusions, Intravenous ,Stroke ,Aged ,business.industry ,Cerebral infarction ,Medicine (all) ,General Medicine ,Thrombolysis ,Middle Aged ,medicine.disease ,Logistic Models ,Treatment Outcome ,Anesthesia ,Tissue Plasminogen Activator ,Acute Disease ,Female ,business ,Intracranial Hemorrhages ,Fibrinolytic agent - Abstract
Background Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke. Methods After exclusion of patients with a brain hemorrhage or major infarction, as detected on a computed tomographic scan, we randomly assigned patients with acute ischemic stroke in a 1:1 double-blind fashion to receive treatment with intravenous alteplase (0.9 mg per kilogram of body weight) or placebo. The primary end point was disability at 90 days, dichotomized as a favorable outcome (a score of 0 or 1 on the modified Rankin scale, which has a range of 0 to 6, with 0 indicating no symptoms at all and 6 indicating death) or an unfavorable outcome (a score of 2 to 6 on the modified Rankin scale). The secondary end point was a global outcome analysis of four neurologic and disability scores combined. Safety end points included death, symptomatic intracranial hemorrhage, and other serious adverse events. Results We enrolled a total of 821 patients in the study and randomly assigned 418 to the alteplase group and 403 to the placebo group. The median time for the administration of alteplase was 3 hours 59 minutes. More patients had a favorable outcome with alte plase than with placebo (52.4% vs. 45.2%; odds ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.76; P = 0.04). In the global analysis, the outcome was also improved with alteplase as compared with placebo (odds ratio, 1.28; 95% CI, 1.00 to 1.65; P
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.